全文获取类型
收费全文 | 962篇 |
免费 | 82篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 21篇 |
妇产科学 | 20篇 |
基础医学 | 291篇 |
口腔科学 | 16篇 |
临床医学 | 85篇 |
内科学 | 156篇 |
皮肤病学 | 26篇 |
神经病学 | 109篇 |
特种医学 | 31篇 |
外科学 | 98篇 |
综合类 | 7篇 |
预防医学 | 35篇 |
眼科学 | 41篇 |
药学 | 45篇 |
肿瘤学 | 55篇 |
出版年
2024年 | 4篇 |
2023年 | 5篇 |
2022年 | 11篇 |
2021年 | 20篇 |
2020年 | 16篇 |
2019年 | 15篇 |
2018年 | 28篇 |
2017年 | 17篇 |
2016年 | 26篇 |
2015年 | 28篇 |
2014年 | 43篇 |
2013年 | 35篇 |
2012年 | 38篇 |
2011年 | 56篇 |
2010年 | 35篇 |
2009年 | 31篇 |
2008年 | 50篇 |
2007年 | 34篇 |
2006年 | 42篇 |
2005年 | 44篇 |
2004年 | 52篇 |
2003年 | 42篇 |
2002年 | 40篇 |
2001年 | 24篇 |
2000年 | 23篇 |
1999年 | 11篇 |
1998年 | 11篇 |
1996年 | 4篇 |
1995年 | 10篇 |
1994年 | 4篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 4篇 |
1989年 | 9篇 |
1988年 | 9篇 |
1987年 | 4篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1955年 | 4篇 |
1944年 | 3篇 |
1943年 | 9篇 |
1942年 | 18篇 |
1941年 | 7篇 |
1939年 | 25篇 |
1938年 | 23篇 |
1937年 | 24篇 |
1936年 | 27篇 |
1935年 | 3篇 |
1932年 | 3篇 |
1927年 | 3篇 |
排序方式: 共有1045条查询结果,搜索用时 31 毫秒
21.
22.
23.
24.
Anika Mann Susann Illing Elke Miess Stefan Schulz 《British journal of pharmacology》2015,172(2):311-316
The efficiency of μ-opioid receptor signalling is tightly regulated and ultimately limited by the coordinated phosphorylation of intracellular serine and threonine residues. Here, we review and discuss recent progress in the generation and application of phosphosite-specific μ-opioid receptor antibodies, which have proved to be excellent tools for monitoring the spatial and temporal dynamics of receptor phosphorylation and dephosphorylation. Agonist-induced phosphorylation of μ-opioid receptors occurs at a conserved 10 residue sequence 370TREHPSTANT379 in the receptor''s carboxyl-terminal cytoplasmic tail. Diverse opioids induce receptor phosphorylation at S375, present in the middle of this sequence, but only high-efficacy opioids have the ability to drive higher order phosphorylation on flanking residues (T370, T376 and T379). S375 is the initiating residue in a hierarchical phosphorylation cascade. In contrast, agonist-independent heterologous μ-opioid receptor phosphorylation occurs primarily at T370. The combination of phosphosite-specific antibodies and siRNA knockdown screening also facilitated the identification of relevant kinases and phosphatases. In fact, morphine induces a selective S375 phosphorylation that is predominantly catalysed by GPCR kinase 5 (GRK5), whereas multisite phosphorylation induced by high-efficacy opioids specifically requires GRK2/3. By contrast, T370 phosphorylation stimulated by phorbol esters or heterologous activation of Gq-coupled receptors is mediated by PKCα. Rapid μ-opioid receptor dephosphorylation occurs at or near the plasma membrane and is catalysed by protein phosphatase 1γ (PP1γ). These findings suggest that there are distinct phosphorylation motifs for homologous and heterologous regulation of μ-opioid receptor phosphorylation. However, it remains to be seen to what extent different μ-opioid receptor phosphorylation patterns contribute to the development of tolerance and dependence in vivo.
LINKED ARTICLES
This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2 相似文献25.
26.
27.
28.
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma 总被引:1,自引:0,他引:1
Shi J Tricot GJ Garg TK Malaviarachchi PA Szmania SM Kellum RE Storrie B Mulder A Shaughnessy JD Barlogie B van Rhee F 《Blood》2008,111(3):1309-1317
Human leukocyte antigen class I molecules expressed by tumor cells play a central role in the regulation of natural killer (NK) cell-mediated immune responses. The proteasome inhibitor bortezomib has demonstrated significant activity in multiple myeloma (MM). We hypothesized that treatment of MM with bortezomib results in the reduction of cell-surface expression of class I and thereby sensitizes MM to NK cell-mediated lysis. Here we report that bortezomib down-regulates class I in a time- and dose-dependent fashion on all MM cell lines and patient MM cells tested. Downregulation of class I can also be induced in vivo after a single dose of 1.0 mg/m(2) bortezomib. Bortezomib significantly enhances the sensitivity of patient myeloma to allogeneic and autologous NK cell-mediated lysis. Further, the level of decrease in class I expression correlates with increased susceptibility to lysis by NK cells. Clinically relevant bortezomib concentrations do not affect NK-cell function. Our findings have clear therapeutic implications for MM and other NK cell-sensitive malignancies in the context of both allogeneic and autologous adoptively transferred NK cells. 相似文献
29.